Author:
Sahi Nitin Kumar,Abidi Syed Muhammad Ali,Salim Omar,Abraham Roby,Kalra Seema,Al-Araji Adnan
Subject
Clinical Neurology,Neurology,General Medicine
Reference10 articles.
1. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases;Baker;Clin. Exp. Immunol.,2020
2. The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis;Baker;Mult. Scler. Relat. Disord.,2020
3. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness;Barun;Mult. Scler. Relat. Disord.,2021
4. Coles A., Lim M., Giovannoni G., et al., 2020. ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the threat of a coronavirus epidemic. Available from: https://www.theabn.org/resource/collection/65C334C7-30FA-45DB-93AA-74B3A3A20293/ABN_Guidance_on_DMTs_for_MS_and_COVID_19_VERSION_18_May_FINAL.pdf [Accessed 20 September 2021].
5. Tailoring B cell depletion therapy in MS according to memory B cell monitoring;Novi;Neurol. Neuroimmunol. Neuroinflamm.,2020
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献